New Drug Futures (Cancer)
Products that could change the pharma market to 2010 and beyond
| Price: £695.00 Approx $1,349.69 (USD) €1,038.06 (EUR) |
|
|---|---|
| Overview: | |
| This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the cancer sector. The report includes unique sales forecasts by major product. |
|
|
This paper is available from one of our partner sites.
Click here for details and to download it. |
|
Publication Date: 19th May 2006
Contents:
NEW DRUG FUTURES
CURRENT MARKET SIZE 1
ADDRESSABLE PATIENT POPULATION 3
CURRENT TREATMENTS 5
surgery.5
radiation5
chemotherapy .5
NoVel theraPies/moNocloNal aNtiboDies ....6
hormoNal theraPies .6
CANCER SALES DRIVERS 7
CANCER SALES BREAKERS . 8
FUTURE TREATMENTS .9
MARKET DYNAMICS - WINNERS & LOSERS 19
KEY DRUG LAUNCHES BY 2010 20
KEY EVALUATION CRITERIA .21
KEY CANCER DRUG LAUNCHES BY 2010 .22
acapodene (gtx) . 22
Novelty/rationale for mechanism of action .22
Proof of concept/clinical data 22
Management/clinical expertise .22
Competition within the marketplace/gaining share of voice .23
Risks associated with developing a drug within a therapeutic class 23
Filings and approval .23
Sales forecasts and assumptions 23
Competitor Ratio Analysis .24
aP23573 (ariad Pharmaceuticals) 24
Novelty/rationale for mechanism of action .24
Proof of concept/clinical data ..24
Management/clinical expertise .25
Competition within the marketplace/gaining share of voice 25
Risks associated with developing a drug within a therapeutic class .25
Filings and approval 25
Sales forecasts and assumptions .25
Competitor Ratio Analysis .26
Dasatinib (bristol-myers squibb) 26
Novelty/rationale for mechanism of action ..26
Proof of concept/clinical data 26
Management/clinical expertise .27
Competition within the marketplace/gaining share of voice .27
Risks associated with developing a drug within a therapeutic class 27
Filings and approval 27
Sales forecasts and assumptions 27
Competitor Ratio Analysis 28
ixabepilone (bristol-myers squibb) .28
Novelty/rationale for mechanism of action ..28
Proof of concept/clinical data .28
Management/clinical expertise .29
Competition within the marketplace/gaining share of voice 29
Risks associated with developing a drug within a therapeutic class .29
Filings and approval 29
Sales forecasts and assumptions .29
Competitor Ratio Analysis 30
lapatinib (glaxosmithkline) 30
Novelty/rationale for mechanism of action .30
Proof of concept/clinical data 30
Management/clinical expertise .30
Competition within the marketplace/gaining share of voice 31
Risks associated with developing a drug within a therapeutic class .31
Filings and approval .31
Sales forecasts and assumptions .31
Competitor Ratio Analysis .32
Nexavar (onyx Pharmaceuticals/bayer) .32
Novelty/rationale for mechanism of action .32
Proof of concept/clinical data 32
Management/clinical expertise .33
Competition within the marketplace/gaining share of voice 33
Risks associated with developing a drug within a therapeutic class 33
Filings and approval 33
Sales forecasts and assumptions .34
Competitor Ratio Analysis 34
Panitumumab(amgen/abgenix) 34
Novelty/rationale for mechanism of action .34
Proof of concept/clinical data .35
Management/clinical expertise 35
Competition within the marketplace/gaining share of voice 35
Risks associated with developing a drug within a therapeutic class 35
Filings and approval .36
Sales forecasts and assumptions 36
Competitor Ratio Analysis .36
revlimid (celgene) 37
Novelty/rationale for mechanism of action .37
Proof of concept/clinical data 37
Management/clinical expertise 37
Competition within the marketplace/gaining share of voice .38
Risks associated with developing a drug within a therapeutic class 38
Filings and approval .38
Sales forecasts and assumptions .38
Competitor Ratio Analysis .39
satraplatin(gPc biotech/spectrum Pharmaceutical) . 39
Novelty/rationale for mechanism of action .39
Proof of concept/clinical data ..39
Management/clinical expertise .41
Competition within the marketplace/gaining share of voice .41
Risks associated with developing a drug within a therapeutic class .41
Filings and approval ..41
Sales forecasts and assumptions .41
Competitor Ratio Analysis .42
sutent (Pfizer) . 42
Novelty/rationale for mechanism of action 42
Proof of concept/clinical data 42
Management/clinical expertise 42
Competition within the marketplace/gaining share of voice .43
Risks associated with developing a drug within a therapeutic class 43
Filings and approval 43
Sales forecasts and assumptions .43
Competitor Ratio Analysis .44
telcyta (telik) . 44
Novelty/rationale for mechanism of action 44
Proof of concept/clinical data .44
Mangement/clinical expertise ..45
Competition within the marketplace/gaining share of voice .45
Risks associated with developing a drug within a therapeutic class .45
Filings and approval ..45
Sales forecasts and assumptions 45
Competitor Ratio Analysis .46
ticilimumab (Pfizer/amgen) . 46
Novelty/rationale for mechanism of action .46
Proof of concept/clinical data .46
Management/clinical expertise .46
Competition within the marketplace/gaining share of voice .47
Risks associated with developing a drug within a therapeutic class 47
Filings and approval .47
Sales forecasts and assumptions .47
Competitor Ratio Analysis .48
Vatalanib (Novartis/schering) . 48
Novelty/rationale for mechanism of action 48
Proof of concept/clinical data .48
Management/clinical expertise .49
Competition within the marketplace/gaining share of voice 49
Risks associated with developing a drug within a therapeutic class 50
Filings and approval .50
Sales forecasts and assumptions .50
Competitor Ratio Analysis .50
COMPETITOR RATIO ANALYSIS SUMMARY .51
COMPETITOR RATIO ANALYSIS - COMPANIES .54